Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi Buys Protein Sciences for $750M | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sanofi Buys Protein Sciences for $750M

Adds recombinant-based influenza vaccine to portfolio

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, CT, for $650 million upfront and as much as $100 million based on certain development milestones. The acquisition, subject to customary regulatory approvals, is expected to close in 3Q17.
 
Protein Sciences received approval from the FDA in October 2016 for their Flublok Quadrivalent Influenza Vaccine (QIV), which is the only recombinant protein-based flu vaccine approved by the FDA. 
 
“The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg based vaccine,” said David Loew, Sanofi executive vice president and head of Sanofi Pasteur, Sanofi’s vaccines division. 

“Protein Sciences was actively looking for an opportunity to grow its business, particularly in the U.S.,” said Manon M.J. Cox, president and chief executive officer, Protein Sciences. “As part of Sanofi Pasteur, we expect our Flublok influenza vaccine to benefit from Sanofi Pasteur’s expertise in the field of influenza vaccines.” 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics